David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences discusses their Partners with Elevation Oncology to Advance Enrollment in Phase 2 Trial of Patients with Solid Tumors Harboring NRG1 Gene Fusions.
IRVING, Texas, Aug. 11, 2020 /PRNewswire/ — Caris Life Sciences ®, a leading molecular science innovator focused on delivering on the promise of precision medicine, today announced it has entered into a strategic alliance with Elevation Oncology to improve patient enrollment procedures for genomically guided, tumor-agnostic clinical trials. Using Caris’ market-leading molecular profiling offerings package, the clinical trial solutions of Caris Pharmatech Just-In-Time ( JIT) and the Caris Precision Oncology AllianceTM (POA) network, companies can boost conventional enrollment in Phase 2 CRESTONE registration-driven Elevation Oncology trial through real-time, nationwide identification of qualified neuregulin-1 patients
We are delighted to collaborate with Elevation Oncology and look forward to working with them to improve their recruiting efforts in clinical trials, with the overall aim of reducing the disease burden for NRG1 fusion-positive patients across a spectrum of solid tumors, said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer. “The future of cancer care depends on today’s clinical trials, and we are eager to use our industry-leading suite of precision medicine innovations to overcome the obstacles usually faced in genomically guided, tumor-agnostic trials.”
Under the terms of the agreement, for inclusion in the CRESTONE trial of Elevation Oncology, Caris will help Elevation Oncology recognize patients with advanced solid tumors that harbor the NRG1 fusions. Eligible patients will be confirmed for inclusion in the Phase 2 CRESTONE seribantumab trial of Elevation Oncology in adult patients with recurrent, locally advanced, or metastatic solid tumors containing the NRG1 fusion gene.
As the first strategic site for CRESTONE, Sarah Cannon Research Institute (Sarah Cannon) has been chosen and is currently open and enrolling patients. Qualified patients, including those inside the Caris Pharmatech oncology trial network and the Caris Precision Oncology Alliance network, will be able to enroll in CRESTONE directly at their local oncology center, reduce travel and keep patients healthy in the face of continuing COVID-19 limitations, and help provide patients who need them with direct care opportunities.
The discovery of oncogenic motors, such as NRG1 gene fusion, through advanced molecular testing is a crucial first step in the treatment journey of a patient, said Shawn Leland, PharmD, RPh, Elevation Oncology Founder and Chief Business Officer. Based on their tumor’s specific genomic signature, physicians may determine for each particular patient the required therapeutics or investigational trials. As an industry, to ensure that the best possible outcome for patients with unusual, genomically induced cancers can be obtained, we must stress the importance of partnerships between diagnostic providers and therapeutic developers.
Please visit www. NRG1fusion.com for more information about seribantumab and the CRESTONE analysis.